NASDAQ · Healthcare · Biotechnology
Rallybio Corporation
RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. CEO Stephen Uden · Market cap $73.0M.
$13.80
-0.23 · -1.64%
52w hi $15.3152w lo $2.16
Off 52w high 4.9%
52
ROUTINE
Current InsiderScore
Corp · 90d
3
3 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
0
0 strong · 0 notable
Analyst consensus
Strong Buy
—
Section 01
Recent Form 4 filings
3 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| May 05 | ADAR1 Capital Management, LLC | Buy | 35,101 | $14.00 | +$491K | 40 | |
| May 04 | ADAR1 Capital Management, LLC | Buy | 3,900 | $13.90 | +$54K | 37 | |
| May 04 | ADAR1 Capital Management, LLC | Buy | 116,904 | $13.97 | +$1.63M | 52 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
JunJulAugSepOctNovDecJanFebMarAprMay